MYGN PE Ratio & Valuation,Is MYGN Overvalued

MYGN Relative Valuation

MYGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MYGN is overvalued; if below, it's undervalued.

Historical Valuation

Myriad Genetics Inc (MYGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.79 is considered Undervalued compared with the five-year average of -13.59. The fair price of Myriad Genetics Inc (MYGN) is between 13.34 to 26.35 according to relative valuation methord. Compared to the current price of 7.00 USD , Myriad Genetics Inc is Undervalued By 47.55%.

Relative Value

Fair Zone

13.34-26.35

Current Price：7.00

47.55%

Undervalued

223.80

21.26

EV/EBITDA

Myriad Genetics Inc. (MYGN) has a current EV/EBITDA of 21.26. The 5-year average EV/EBITDA is 38.99. The thresholds are as follows: Strongly Undervalued below -131.62, Undervalued between -131.62 and -46.31, Fairly Valued between 124.29 and -46.31, Overvalued between 124.29 and 209.59, and Strongly Overvalued above 209.59. The current Forward EV/EBITDA of 21.26 falls within the Historic Trend Line -Fairly Valued range.

76.94

EV/EBIT

Myriad Genetics Inc. (MYGN) has a current EV/EBIT of 76.94. The 5-year average EV/EBIT is -3732.57. The thresholds are as follows: Strongly Undervalued below -36758.57, Undervalued between -36758.57 and -20245.57, Fairly Valued between 12780.43 and -20245.57, Overvalued between 12780.43 and 29293.43, and Strongly Overvalued above 29293.43. The current Forward EV/EBIT of 76.94 falls within the Historic Trend Line -Fairly Valued range.

0.79

Myriad Genetics Inc. (MYGN) has a current PS of 0.79. The 5-year average PS is 2.27. The thresholds are as follows: Strongly Undervalued below 0.44, Undervalued between 0.44 and 1.36, Fairly Valued between 3.19 and 1.36, Overvalued between 3.19 and 4.10, and Strongly Overvalued above 4.10. The current Forward PS of 0.79 falls within the Undervalued range.

29.74

P/OCF

Myriad Genetics Inc. (MYGN) has a current P/OCF of 29.74. The 5-year average P/OCF is 38.31. The thresholds are as follows: Strongly Undervalued below -214.71, Undervalued between -214.71 and -88.20, Fairly Valued between 164.82 and -88.20, Overvalued between 164.82 and 291.33, and Strongly Overvalued above 291.33. The current Forward P/OCF of 29.74 falls within the Historic Trend Line -Fairly Valued range.

-480.05

P/FCF

Myriad Genetics Inc. (MYGN) has a current P/FCF of -480.05. The 5-year average P/FCF is -28.33. The thresholds are as follows: Strongly Undervalued below -431.72, Undervalued between -431.72 and -230.03, Fairly Valued between 173.36 and -230.03, Overvalued between 173.36 and 375.05, and Strongly Overvalued above 375.05. The current Forward P/FCF of -480.05 falls within the Strongly Undervalued range.

Myriad Genetics Inc (MYGN) has a current Price-to-Book (P/B) ratio of 1.80. Compared to its 3-year average P/B ratio of 2.04 , the current P/B ratio is approximately -11.58% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about -14.51% higher. Myriad Genetics Inc (MYGN) has a Forward Free Cash Flow (FCF) yield of approximately -2.48%. Compared to its 3-year average FCF yield of -6.99%, the current FCF yield is approximately -64.45% lower. Relative to its 5-year average FCF yield of -5.54% , the current FCF yield is about -55.12% lower.

1.75

P/B

Median3y

2.04

Median5y

2.11

-2.48

FCF Yield

Median3y

-6.99

Median5y

-5.54

Competitors Valuation Multiple

The average P/S ratio for MYGN's competitors is , providing a benchmark for relative valuation. Myriad Genetics Inc Corp (MYGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -3.56%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of MYGN decreased by 49.02% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -10.36 to -13.32.

The secondary factor is the Revenue Growth, contributed -3.56%to the performance.

Overall, the performance of MYGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-3.56%

213.30M → 205.70M

Revenue Growth

28.57%

-10.36 → -13.32

Margin Expansion

-74.03%

-6.19 → -1.61

P/E Change

-49.02%

13.71 → 6.99

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Myriad Genetics Inc (MYGN) currently overvalued or undervalued?

What is Myriad Genetics Inc (MYGN) fair value?

MYGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Myriad Genetics Inc (MYGN) is between 13.34 to 26.35 according to relative valuation methord.

How does MYGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Myriad Genetics Inc (MYGN) as of Dec 16 2025?

As of Dec 16 2025, Myriad Genetics Inc (MYGN) has a P/B ratio of 1.80. This indicates that the market values MYGN at 1.80 times its book value.

What is the current FCF Yield for Myriad Genetics Inc (MYGN) as of Dec 16 2025?

As of Dec 16 2025, Myriad Genetics Inc (MYGN) has a FCF Yield of -2.48%. This means that for every dollar of Myriad Genetics Inc’s market capitalization, the company generates -2.48 cents in free cash flow.

What is the current Forward P/E ratio for Myriad Genetics Inc (MYGN) as of Dec 16 2025?

As of Dec 16 2025, Myriad Genetics Inc (MYGN) has a Forward P/E ratio of 230.51. This means the market is willing to pay $230.51 for every dollar of Myriad Genetics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Myriad Genetics Inc (MYGN) as of Dec 16 2025?

As of Dec 16 2025, Myriad Genetics Inc (MYGN) has a Forward P/S ratio of 0.79. This means the market is valuing MYGN at $0.79 for every dollar of expected revenue over the next 12 months.

MYGN Valuation